EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America



Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America



Head & Neck 25(9): 717-731



Background: The objective was to evaluate the efficacy and safety of a novel intratumoral cisplatin/epinephrine injectable gel (CDDP/epi gel) for local control and palliation of tumor-related symptoms in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients and Methods: Eighty-seven patients were randomly assigned to either CDDP/epi or placebo gel in this phase III, double-blind study. Tumors were ltoreq20 cm3; most recurrences (88%) were in a previously irradiated field. The most symptomatic or threatening tumor was designated as the target tumor. Dose: 0.25 mL CDDP/epi gel/cm3 tumor volume. Treatments: ltoreq6 weekly intratumoral injections in an 8-week period. Primary outcomes: target tumor response and symptom relief. Results: During the blinded phase, 34% (21 of 62) of patients achieved an objective response (CR or PR) in the target tumor treated with CDDP/epi gel vs 0% (0 of 24) treated with placebo gel (p<.001 ). Responses occurred within a median of four treatments (range, 2-6) and were durable (median, 95 days; range, 34-168+ days). More patients treated with CDDP/epi gel achieved palliative benefit than did those treated with placebo gel (37% vs 12%, p=.036). Most frequent side effects were local pain and local cutaneous reactions, which resolved over 3-12 weeks. Renal and hematologic toxicities were rare. Conclusions: This phase III trial showed that CDDP/epi gel significantly reduces tumor burden, palliates tumor-related symptoms, and is an effective local treatment for recurrent tumors.

(PDF emailed within 0-6 h: $19.90)

Accession: 010876448

Download citation: RISBibTeXText

PMID: 12953307

DOI: 10.1002/hed.10261



Related references

Treatment of advanced head and neck squamous cell carcinoma with intratumoral cisplatin/epinephrine injectable gel Phase III multicenter studies. European Journal of Cancer 37(Supplement 6): S102, October, 2001

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer 118(19): 4694-4705, 2012

A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist 20(10): 1119-1120, 2016

Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. European Journal of Cancer 52(): 77-84, 2016

Neo-adjuvant chemo- -therapy of advanced squamous-cell head and neck carcinoma A multicenter, phase III, randomized study comparing cisplatin plus 5-fluorouracil with cisplatin plus 5-FU plus recombinant interleukin 2. Cancer Immunology Immunotherapy 47(3): 149-156, 1998

Neo-adjuvant chemo-(immuno)-therapy of advanced squamous-cell head and neck carcinoma: A multicenter, phase III, randomized study comparing cisplatin plus 5-fluorouracil (5-FU) with cisplatin plus 5-FU plus recombinant interleukin 2. Cancer Immunology Immunotherapy 47(3): 149-156, 1998

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunology, ImmunoTherapy 47(3): 149-156, 1998

A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel. British Journal of Cancer 87(9): 938-944, 2002

Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Annals of Otology, Rhinology, and Laryngology 113(3 Pt 1): 229-233, 2004

Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Onkologie 18(SUPPL 2): 93, 1995

Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. RadioTherapy and Oncology 100(1): 62-69, 2011

Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). Cancer ChemoTherapy and Pharmacology 62(2): 253-261, 2007

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 15(): 469-469, 2015

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. Bmc Cancer 13: 102-102, 2013

Reduced infections with perioperative immunonutrition in head and neck cancer: exploratory results of a multicenter, prospective, randomized, double-blind study. Clinical Nutrition 33(5): 776-784, 2015